← Human Trials & Peer-Reviewed Studies
Reduced weight gain with insulin detemir compared to NPH insulin is not explained by a reduction in hypoglycemia
Plain-language guide to PMID 18715200 (2008): double-blind randomized controlled trial study of Insulin Detemir and NPH Insulin (isophane).
Key Facts
- PMID
- 18715200
- Journal
- Diabetes technology & therapeutics
- Year
- 2008
- Study type
- Randomized Controlled Trial
- Authors
- Davies MJ et al. (4 authors)
- DOI
- 10.1089/dia.2008.0282
- Registered trial
- NCT00604396
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial paper looks at Insulin Detemir and NPH Insulin (isophane).
The aim of this exploratory analysis was to investigate any correlations between weight change and occurrence of hypoglycemia with NPH insulin and insulin detemir.
Why It Was Studied
Weight gain often occurs when insulin therapy is initiated.
Who Took Part
A total of 476 insulin-naive patients with type 2 diabetes treated with one or two OADs added insulin detemir (n=237) or NPH insulin (n=239) morning and evening to their current oral treatment.
How the Study Was Run
The design is described as randomized, double-blind, open-label, multicenter and parallel-group.
The participants were allocated by chance, so the Insulin Detemir group and the comparison group should start out alike.
Blinding on both sides kept the participants and researchers unaware of who received Insulin Detemir.
Everyone knew when Insulin Detemir was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.
More than one site took part, so the participants came from several places.
The analysis was based on a 26-week, randomized, multicenter, open-label, parallel-group trial in which glycemic control, hypoglycemia, and weight change were compared between insulin detemir and NPH insulin.
Weight gain data from this study were analyzed as a function of hypoglycemia frequency.
What Was Measured
Topics PubMed links to this paper include Blood Glucose, Diabetes Mellitus, Type 2, Glycated Hemoglobin, Hypoglycemia, Hypoglycemic Agents, Insulin and Insulin Detemir.
What This Means in Plain Language
The paper is a randomized, double-blind and open-label study of Insulin Detemir and NPH Insulin (isophane).
Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2008 (Diabetes technology & therapeutics), a journal based in United States.
More context: the Insulin Detemir compound page and the NPH Insulin (isophane) compound page.
Our Notes on the Compounds
Insulin Detemir: A long-acting basal insulin analog sold as Levemir.
NPH Insulin (isophane): An intermediate-acting insulin made by combining insulin with protamine; also called isophane or NPH insulin (Humulin N, Novolin N).
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.